Esomeprazole and Utilins of Laimei Pharmaceutical Co., Ltd. have completed the on-site inspection of GMP certification

GMP certification is the final review link before the new drugs are put on the market Insiders generally expect that the two new drugs are expected to be put on the market in the first half of this year Laimei pharmaceutical is mainly engaged in anti infection products, specialty products and large infusion products Esomeprazole and Utilins, as the two heaviest new drugs of the company, have attracted market attention Esomeprazole is the latest generation of proton pump inhibitors The original research drug is AstraZeneca star drug "nexin" Its sales volume in 2010 and 2012 ranked first in the digestive prescription drugs in the United States According to the Research Report of GF Securities, the global annual sales of esomeprazole exceed 8 billion US dollars, and the domestic hospital terminal sales are 2.5 billion US dollars According to the website information of CFDA, only AstraZeneca and Laimei pharmaceutical are approved to produce Esomeprazole in China, and Laimei pharmaceutical products will share the domestic market with AstraZeneca after being listed Utilins is an adjuvant immunomodulator mainly used in the treatment of pulmonary and extrapulmonary tuberculosis, which has entered the national medical insurance catalogue Jinxing pharmaceutical, a subsidiary of Laimei pharmaceutical, is the only enterprise in China that has the approval of the drug From 2008 to 2009, Jinxing pharmaceutical industry realized operating revenue of 24.613 million yuan and 31.788 million yuan respectively, up 29% year on year; net profit of 5.621 million yuan and 14.988 million yuan, up 167% year on year Since then, due to the Wenchuan earthquake, the product has been in a state of shutdown since August 2009